Endometrial cancer-associated mutants of SPOP are defective in regulating estrogen receptor-α protein turnover

Cell Death and Disease

Volumn 6, Issue 3, 2015, Pages

  Zhang, P ^a,b   Gao, K ^a   Jin, X ^a   Ma, J ^c   Peng, J ^c   Wumaier, R ^a   Tang, Y ^a   Zhang, Y ^a   An, J ^d   Yan, Q ^e   Dong, Y ^f   Huang, H ^d   Yu, L ^a,b   Wang, C ^a  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^d MAYO GRADUATE SCHOOL   (United States)

^e SHANGHAI JIAO TONG UNIVERSITY   (China)

^f UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARRIER PROTEIN; CUL3 PROTEIN, HUMAN; CULLIN; ESTROGEN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR ALPHA, HUMAN; NUCLEAR PROTEIN; PROTEASOME; RBX1 PROTEIN, HUMAN; REPRESSOR PROTEIN; SPOP PROTEIN, HUMAN; UBIQUITIN PROTEIN LIGASE;

ENDOMETRIUM TUMOR; FEMALE; GENETICS; HUMAN; METABOLISM; MUTATION; PATHOLOGY; PROTEIN DEGRADATION; TUMOR CELL LINE; UBIQUITINATION;

CARRIER PROTEINS; CELL LINE, TUMOR; CULLIN PROTEINS; ENDOMETRIAL NEOPLASMS; ESTROGEN RECEPTOR ALPHA; ESTROGENS; FEMALE; HUMANS; MUTATION; NUCLEAR PROTEINS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEOLYSIS; REPRESSOR PROTEINS; UBIQUITIN-PROTEIN LIGASES; UBIQUITINATION;

EID: 84965085978     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/CDDIS.2015.47     Document Type: Article

References (26)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010; 127: 2893–2917.
2. Sutton G, Axelrod JH, Bundy BN, Roy T, Homesley HD, Malfetano JH et al. Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study. Gynecol Oncol 2005; 97: 755–763.
3. Le Gallo M, O'Hara AJ, Rudd ML, Urick ME, Hansen NF, O'Neil NJ et al. Exome sequencing of serous endometrial tumors identifies recurrent somatic mutations in chromatin-remodeling and ubiquitin ligase complex genes. Nat Genet 2012; 44: 1310–1315.
4. Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H et al. Integrated genomic characterization of endometrial carcinoma. Nature 2013; 497: 67–73.
5. Zhao S, Choi M, Overton JD, Bellone S, Roque DM, Cocco E et al. Landscape of somatic single-nucleotide and copy-number mutations in uterine serous carcinoma. Proc Natl Acad Sci USA 2013; 110: 2916–2921.
6. Kuhn E, Wu RC, Guan B, Wu G, Zhang J, Wang Y et al. Identification of molecular pathway aberrations in uterine serous carcinoma by genome-wide analyses. J Natl Cancer Inst 2012; 104: 1503–1513.
7. Le Gallo M, Bell DW. The emerging genomic landscape of endometrial cancer. Clin Chem 2014; 60: 98–110.
8. Genschik P, Sumara I, Lechner E. The emerging family of CULLIN3-RING ubiquitin ligases (CRL3s): cellular functions and disease implications. Embo J 2013; 32: 2307–2320.
9. Li C, Ao J, Fu J, Lee DF, Xu J, Lonard D et al. Tumor-suppressor role for the SPOP ubiquitin ligase in signal-dependent proteolysis of the oncogenic co-activator SRC-3/AIB1. Oncogene 2011; 30: 4350–4364.
10. Kwon JE, La M, Oh KH, Oh YM, Kim GR, Seol JH et al. BTB domain-containing speckle-type POZ protein (SPOP) serves as an adaptor of Daxx for ubiquitination by Cul3-based ubiquitin ligase. J Biol Chem 2006; 281: 12664–12672.
11. Zhang Q, Shi Q, Chen Y, Yue T, Li S, Wang B et al. Multiple Ser/Thr-rich degrons mediate the degradation of Ci/Gli by the Cul3-HIB/SPOP E3 ubiquitin ligase. Proc Natl Acad Sci USA 2009; 106: 21191–21196.
12. Liu J, Ghanim M, Xue L, Brown CD, Iossifov I, Angeletti C et al. Analysis of Drosophila segmentation network identifies a JNK pathway factor overexpressed in kidney cancer. Science 2009; 323: 1218–1222.
13. Hernandez-Munoz I, Lund AH, van der Stoop P, Boutsma E, Muijrers I, Verhoeven E et al. Stable X chromosome inactivation involves the PRC1 Polycomb complex and requires histone MACROH2A1 and the CULLIN3/SPOP ubiquitin E3 ligase. Proc Natl Acad Sci USA 2005; 102: 7635–7640.
14. Blattner M, Lee DJ, O'Reilly C, Park K, MacDonald TY, Khani F et al. SPOP mutations in prostate cancer across demographically diverse patient cohorts. Neoplasia 2014; 16:14–20.
15. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 2012; 44: 685–689.
16. Zhou W, Slingerland JM. Links between oestrogen receptor activation and proteolysis: relevance to hormone-regulated cancer therapy. Nat Rev Cancer 2014; 14: 26–38.
17. Osborne CK, Schiff R, Fuqua SA, Shou J. Estrogen receptor: current understanding of its activation and modulation. Clin Cancer Res 2001; 7: 4338s–4342s. Discussion 4411s–4412s.
18. Beato M, Herrlich P, Schutz G. Steroid hormone receptors: many actors in search of a plot. Cell 1995; 83: 851–857.
19. An J, Wang C, Deng Y, Yu L, Huang H. Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants. Cell Rep 2014; 6: 657–669.
20. Rajbhandari P, Schalper KA, Solodin NM, Ellison-Zelski SJ, Ping LK, Rimm DL et al. Pin1 modulates ERalpha levels in breast cancer through inhibition of phosphorylation-dependent ubiquitination and degradation. Oncogene 2014; 33: 1438–1447.
21. Nawaz Z, Lonard DM, Dennis AP, Smith CL, O'Malley BW. Proteasome-dependent degradation of the human estrogen receptor. Proc Natl Acad Sci USA 1999; 96: 1858–1862.
22. Dauvois S, Danielian PS, White R, Parker MG. Antiestrogen ICI 164,384 reduces cellular estrogen receptor content by increasing its turnover. Proc Natl Acad Sci USA 1992; 89: 4037–4041.
23. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993; 106: 1377–1388.
24. Zhuang M, Calabrese MF, Liu J, Waddell MB, Nourse A, Hammel M et al. Structures of SPOP-substrate complexes: insights into molecular architectures of BTB-Cul3 ubiquitin ligases. Mol Cell 2009; 36: 39–50.
25. Errington WJ, Khan MQ, Bueler SA, Rubinstein JL, Chakrabartty A, Prive GG. Adaptor protein self-assembly drives the control of a cullin-RING ubiquitin ligase. Structure 2012; 20: 1141–1153.
26. Hurvitz SA, Pietras RJ. Rational management of endocrine resistance in breast cancer: a comprehensive review of estrogen receptor biology, treatment options, and future directions. Cancer 2008; 113: 2385–2397.